SYK
Market read
The latest filing evidence is available. 0 of 20 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 17 directly disclosed connections are confirming.
Invalidation: The isolated read changes if SYK's group or a disclosed connection begins moving with it.
Research brief
The latest filing evidence is available. 0 of 20 group members are active now; 0 filing-linked outsiders are moving with the group, and 0 of 17 directly disclosed connections are confirming.
Company research
Use the company’s filings to identify the few operating, demand, cost, capital and regulatory variables that determine its earnings power.
Reported annual revenue and per-share history. This is accounting history, not a forecast.
What management says matters
“The increase in Orthopaedics operating income as a percentage of net sales for the six months was primarily driven by lower selling, general and administrative expenses, lower research, development and engineering expenses and higher unit volumes, partially o…”10-Q · Jul 31, 2026 ↗
“The decrease in interest expense in the three months and six months 2026 from 2025 was due to lower outstanding debt and credit facilities partially offset by higher average interest rates.”10-Q · Jul 31, 2026 ↗
“7 STRYKER CORPORATION 2025 FORM 10-K projects, the inability to realize the expected benefits, savings or synergies from the acquisition, the loss of key personnel, litigation resulting from the acquisition and exposure to unexpected liabilities of acquired c…”10-K · Feb 11, 2026 ↗
“Gross profit as a percentage of net sales increased to 63.9% in 2024 from 63.7% in 2023 due to higher sales pricing and favorable volume offset by higher manufacturing and supply chain costs primarily due to inflationary pressures impacting fixed and variable…”10-K · Feb 11, 2026 ↗
Valuation discipline
Price/sales 4.2× · EV/sales 4.6×. Comparisons use only industry-matched filing peers.
Mechanical 2.0-year scenarios are available as editable assumptions, not consensus.
Price action
Jodie does not have enough daily observations to draw a useful short-term chart for this asset. The latest quoted price was checked 11 Sept, 12:10 GMT-4; this is a coverage limitation, not a flat-price conclusion.
Developments
Jodie has not returned a relevant primary source or news item for SYK. This is an evidence-coverage gap, not a conclusion that nothing material happened.
Business and financial condition
Jodie has not returned structured SEC XBRL fundamentals for this asset. This is a coverage limitation, not an assessment of the business or its financial health.
Latest filing assessment · baseline
10-Q filed 2026-05-11 against the comparable filing from 2025-05-02.
“The key components of the change were: Gross Profit Percent Net Sales Three Months 2025 63.8 % Sales pricing 10 bps Volume and mix 10 bps Manufacturing and supply chain costs (200) bps Structural optimization and other special charges 70 bps Inventory stepped up to fair value 60 bps Three Months 2026 63.3 % Gross profit as a percentage of net sales in the three months 2026 decreased to 63.3% from 63.8% in 2025 driven by higher manufacturing and supply chain costs primarily due to idle production time related to the cybersecurity incident.”
“The increase in interest expense in the three months 2026 from 2025 was primarily due to 2025 debt issuances.”
“The key components of the change were: Operating Income Percent Net Sales MedSurg and Neurotechnology Orthopaedics Three Months 2025 24.8 % 30.4 % Sales pricing 20 bps 0 bps Volume 20 bps (10) bps Manufacturing and supply chain costs (220) bps (190) bps Research, development and engineering expenses (40) bps 40 bps Selling, general and administrative expenses (80) bps 130 bps Three Months 2026 21.8 % 30.1 % The decrease in MedSurg and Neurotechnology operating income as a percentage of net sales for the three months was primarily driven by higher manufacturing and supply chain costs due to idle production time related to the cybersecurity incident, higher selling, general and administrative...”
Retrospective baseline calibration. It was generated after the filing date and is not part of Jodie's live track record.
Business ecosystem
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depends on
“We are one of five leading global competitors in Medical; the other four being Baxter International Inc., Zoll Medical Corporation, Medline Industries and Ferno-Washington, Inc.”
“We are one of five leading global competitors in Instruments; the other four being Zimmer Biomet Holdings, Inc.”
Depended on by
“Net sales from our largest two customers, Intuitive Surgical SARL and Stryker Corporation, were 24.3% and 21.5%, respectively, of our total net sales for the year ended December 31, 2025.”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 14 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
SYK is currently a Follower in the organic co-movement group Medical Devices. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.
Context history
No durable theme membership has been observed for this name yet.